CAJ | 학술논문

血管活性肠肽(VIP)是心肺系统最丰富的肽类物质之一,具有强大的抗炎、肺血管与气道舒张作用,以及免疫调节、调节气道分泌等广泛的生物学作用,可减缓COPD相关肺动脉高压(PH)的进展.然而,由于其血浆半衰期较短,给药途径困难,故临床有待进一步研究.本文就现阶段VIP对COPD相关PH治疗的研究进展作一综述.
혈관활성장태(VIP)시심폐계통최봉부적태류물질지일,구유강대적항염、폐혈관여기도서장작용,이급면역조절、조절기도분비등엄범적생물학작용,가감완COPD상관폐동맥고압(PH)적진전.연이,유우기혈장반쇠기교단,급약도경곤난,고림상유대진일보연구.본문취현계단VIP대COPD상관PH치료적연구진전작일종술.
Vasoactive intestinal peptide (VIP) is one of the most abundant peptide in cardiopulmonary system,which has a wide range of biological effects,like a powerful anti-inflammatory effect,powerful vascular/ airway relaxant effect,as well as immune regulation and regulation airway secretion,can slow down chronic obstructive pulmonary disease (COPD)-related pulmonary hypertension (PH) progress.However,because of its short plasma half-life,route of administration difficulties,so VIP need further study in the clinical use.In this paper,the present stage of COPD-related PH which is treated by VIP progress is reviewed.